Improving Distribution Efficiency for an Era of 80% Generic Medicines
First written in FY2016. 21 of 23 entries say "Restated". Latest entry: FY2025-H1.
1 other company's latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「In the pharmaceutical manufacturing and marketing business, we worked to stably supply high-quality, high-value-added pharmaceuticals through rigorous quality control based on our proprietary testing system and the development of a planned production structure.」
The company continues its policy of stably supplying high-quality, high-value-added pharmaceuticals through quality control using its proprietary testing system and a planned production structure. - FY2024-Q3RestatedAnnual report
「In the pharmaceutical manufacturing and marketing business, we worked to stably supply high-quality, high-value-added pharmaceuticals through rigorous quality control based on our proprietary testing system and the development of a planned production structure.」
The company reconfirms its policy of stably supplying high-quality, high-value-added pharmaceuticals through quality control using its proprietary testing system and a planned production structure. - FY2024-Q1RestatedAnnual report
「In the pharmaceutical manufacturing and marketing business, we worked to stably supply high-quality, high-value-added pharmaceuticals through rigorous quality control based on our proprietary testing system and the development of a planned production structure.」
The company reconfirms its policy of stably supplying high-quality, high-value-added generic medicines and other products through quality control using its proprietary testing system and a planned production structure. - FY2022-Q2RestatedAnnual report
「③ Stable supply of quality-assured generic medicines based on proprietary testing in the era of an 80% target volume share for generic medicines」
Based on the premise of an era when generics account for 80% of volume, the company reconfirms ensuring quality through its own testing and maintaining stable supply as key measures. - FY2022-Q1RestatedAnnual report
「In addition, we expanded the generic medicine product lineup, including by newly launching 3 ingredients and 6 products in the supplementary drug price listing in June this year. As of the end of June 2021, generic medicines on sale totaled 85 ingredients and 202 products.」
The company continues to launch new generic medicines and expand its product lineup. The target wording of an 80% volume share is not explicitly stated in this filing. - FY2021-Q3RestatedAnnual report
「In addition, we expanded the generic medicine product lineup, including by newly launching 2 ingredients and 7 products in December 2020. As of the end of December 2020, products on sale totaled 83 ingredients and 202 products.」
The company continues initiatives to expand the generic medicine product lineup and maintain stable supply. The 80% volume share wording itself is not included in this filing. - FY2020RaisedAnnual report
「In preparation for an era when generics account for more than 80% of volume, we will stably supply generic medicines whose quality has been assured through our own testing」
The wording has shifted from the previous “era when generics account for 80% of volume” to an “era when they account for more than 80%,” broadening the assumed market scope. - FY2020-Q3RestatedAnnual report
「We are also pursuing measures to improve profitability, including upgrading logistics capabilities, optimizing delivery frequency and consolidating generic pharmaceuticals through products supplied by 共創未来ファーマ.」
The company continues to consolidate generic medicines around Kyoso Mirai Pharma products as a measure to improve profitability. Its policy in preparation for the era when generics account for 80% of volume remains unchanged. - FY2020-Q2RestatedAnnual report
「We are also pursuing measures to improve profitability, including upgrading logistics capabilities, optimizing delivery frequency and consolidating generic pharmaceuticals through products supplied by 共創未来ファーマ.」
The company continues to consolidate generic medicines around Kyoso Mirai Pharma products as a measure to improve profitability. Its policy in preparation for the era when generics account for 80% of volume remains unchanged. - FY2020-Q1RestatedAnnual report
「We are also pursuing measures to improve profitability, including upgrading logistics capabilities, optimizing delivery frequency and consolidating generic pharmaceuticals through products supplied by 共創未来ファーマ.」
The company continues to consolidate generic medicines around Kyoso Mirai Pharma products as a measure to improve profitability. - FY2019RestatedAnnual report
「In addition, in preparation for the era when generic medicines account for 80% of volume, we will stably supply generic medicines whose quality has been assured through our own testing.」
Based on the premise of an era when generic medicines account for 80% of volume, the company reconfirms its policy of ensuring quality through its own testing and maintaining stable supply. - FY2019-Q3RestatedAnnual report
「Kyoso Mirai Pharma Co., Ltd. continues to stably supply high-quality, high-value-added generic medicines while expanding its product lineup. As of 1 February 2019, its products on sale totaled 62 ingredients and 128 products.」
The company continues to stably supply high-quality, high-value-added generic medicines and expand its product lineup. Specific growth in the number of products is tracked in t27. - FY2019-Q2RestatedAnnual report
「Kyoso Mirai Pharma Co., Ltd., established in preparation for the era when generics account for 80% of volume, continues to stably supply high-quality, high-value-added generic medicines and expand its product lineup. As of the end of October 2018, its products on sale totaled 34 ingredients and 74 products.」
In preparation for the era when generics account for 80% of volume, the company continues to stably supply high-quality, high-value-added products and expand its lineup. Specific progress in the number of products is tracked in t27. - FY2019-Q1RestatedAnnual report
「In its second year since establishment, Kyoso Mirai Pharma Co., Ltd. continues to stably supply high-quality, high-value-added generic medicines while expanding its product lineup.」
The company continues to enhance the quality and value-added of generic medicines and maintain stable supply. The 80% volume share figure is not explicitly stated in this filing. - FY2018RestatedAnnual report
「In addition, in preparation for the era when generics account for 80% of volume, we will stably supply generic medicines whose quality has been assured through our own testing.」
Based on the premise of an era when generics account for 80% of volume, the company reconfirms its policy of ensuring quality through its own testing and maintaining stable supply in the full-year results. - FY2018-Q3RestatedAnnual report
「During the cumulative third-quarter period, the prescription pharmaceutical market remained in a difficult environment due to the advancement of measures to contain healthcare costs, including the promotion of generic medicine use.」
The company reconfirms the business environment in which measures to contain healthcare costs, including the promotion of generic medicine use, continue. - FY2018-Q2RestatedAnnual report
「Kyoso Mirai Pharma Co., Ltd., established last November in preparation for the era when generics account for 80% of volume, obtained its first marketing authorization under the Kyoso Mirai Pharma brand in August for 6 ingredients and 15 products. In September, it newly launched 2 ingredients and 5 products, bringing the number of products launched to 6 ingredients and 19 products.」
The company continues its policy of preparing for the era when generics account for 80% of volume. Specific product development by Kyoso Mirai Pharma is tracked in t27 as progress under the integrated manufacturing and marketing business model. - FY2018-Q1RestatedAnnual report
「In addition, regarding Kyoso Mirai Pharma Co., Ltd., established last November in preparation for the era when generic medicines account for 80% of volume, 2 ingredients and 11 products were newly launched in the supplementary drug price listing in June, bringing the Kyoso Mirai Pharma brand's products to 4 ingredients and 14 products.」
The company reconfirms its policy of preparing for the era when generics account for 80% of volume and continues to supply products through Kyoso Mirai Pharma. Specific product launches are tracked in t27. - FY2017RestatedAnnual report
「In addition, in preparation for the era when generics account for 80% of volume, we will build an integrated manufacturing and marketing supply chain that will stably supply generic medicines whose quality has been assured through our own testing, based on demand forecasts」
The company reiterates the premise of an era in which generics account for 80% of volume and identifies supply chain development, including quality testing, demand forecasting, and stable supply, as specific means of execution. - FY2017-Q3RestatedAnnual report
「Amid the advancement of measures to contain healthcare costs, including revisions to medical fees to promote further use of generic medicines」
The company reconfirms the business environment in which measures to contain healthcare costs, including the promotion of generic medicine use, are advancing. - FY2017-Q2RestatedAnnual report
「Amid the advancement of measures to contain healthcare costs, including a 7.8% reduction in official drug prices, including the special measure for market expansion repricing implemented in April this year, and revisions to medical fees to promote further use of generic medicines」
The company reconfirms the progress of measures to contain healthcare costs, including the promotion of generic medicine use, as part of the business environment. - FY2017-Q1RestatedAnnual report
「Measures to contain healthcare costs, including revisions to medical fees to promote further use of generic medicines, continued to advance.」
The company reiterates the environment surrounding efforts to promote further use of generic medicines, but the figure of 80% is not reiterated in this quarterly report. - FY2016First statedAnnual report
「Further improving the efficiency and value-added of pharmaceutical distribution in preparation for the era of 80% generic medicines」
The company is setting out a direction to improve the efficiency and value-added of pharmaceutical distribution based on a market environment in which generics account for 80%.